Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Diseases × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 29 Triple Negative Breast Neoplasms 13 Prostatic Neoplasms 13 Ovarian Neoplasms 12 Neoplasms 12 Neoplasm Metastasis 9 Fallopian Tube Neoplasms 6 Leukemia, Myeloid, Acute 5 Small Cell Lung Carcinoma 4 Pancreatic Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Carcinoma, Renal Cell 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Solid Tumor 1 Sarcoma 1

Interventions

padeliporfin 5 darolutamide 3 Pluvicto 3 gallium 68 PSMA-11 2 enzalutamide 2 apalutamide 2 Radiotherapy 2 Nivolumab 2 Androgen Antagonists 2 Abiraterone Acetate 2 talazoparib 1 sipuleucel-T 1 palladium-bacteriopheophorbide 1 onapristone 1 olaparib 1 niraparib 1 luprolide acetate gel depot 1 ixabepilone 1 gedatolisib 1 abiraterone 1 Therapeutics 1 Tamsulosin 1 Surveys and Questionnaires 1 Standard of Care 1 Robotic Surgical Procedures 1 Prostate-Specific Antigen 1 Prednisone 1 Paclitaxel 1 Oxygen 1 Nitrous Oxide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06582628 2024-12-02

TEAM PC

Fundacion Oncosur

Phase 2 Recruiting

Prostatic Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡